Table 2 Economic burden of NCDs in Iran in IRR trillions, 2018
From: Prevention and control of non-communicable diseases in iran: the case for Investment
Cost | CVD | Cancer | Diabetes | Respiratory diseases | Total |
|---|---|---|---|---|---|
Direct costs | |||||
Total healthcare expenditures | 174.54 | 87.27 | 52.05 | 75.45 | 389.31 |
Indirect costs | |||||
Cost of absenteeism | 18.3 | - | 2.986 | - | 23.86 |
Cost of presenteeism | 104.7 | - | 73.726 | - | 181 |
Cost of premature death | 137.41 | 101.55 | 1.936 | 8.55 | 244.32 |
Total indirect costs | 260.41 | 101.55 | 77.016 | 8.55 | 449.18 |
Total costs | |||||
Total costs | 434.95 | 188.82 | 130.7 | 84 | 838.49 |